Positive data for Xofluza published in New England Journal of Medicine

6 September 2018

A new abstract, published in the New England Journal of Medicine, details results from the Phase III CAPSTONE-1 study of Xofluza (baloxavir marboxil), which compares the therapy with placebo and oseltamivir in flu patients.

The data were previously presented at Infectious Disease Week in 2017. Xofluza is under joint development by Japan’s Shionogi (TYO: 4507) and Switzerland’s Roche (ROG: SIX).

The data show that median time to alleviation of symptoms for the test group was shorter than for those treated with oseltamivir, which is marketed by Roche and its US-based subsidiary Genentech as Tamiflu.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK